Mn Services Vermogensbeheer B.V. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,868 shares of the life sciences company’s stock after purchasing an additional 600 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Illumina were worth $8,761,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Janney Montgomery Scott LLC raised its position in Illumina by 10.0% in the second quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock worth $6,579,000 after acquiring an additional 2,141 shares in the last quarter. Standard Life Aberdeen plc raised its position in Illumina by 31.1% in the second quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after acquiring an additional 8,199 shares in the last quarter. Waters Parkerson & CO. LLC purchased a new position in Illumina in the second quarter worth $223,000. Bank of Nova Scotia raised its position in Illumina by 216.4% in the second quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after acquiring an additional 40,478 shares in the last quarter. Finally, Eqis Capital Management Inc. raised its position in Illumina by 40.7% in the second quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock worth $2,702,000 after acquiring an additional 2,797 shares in the last quarter. 89.90% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have issued reports on the company. UBS Group assumed coverage on Illumina in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price objective for the company. Barclays increased their price objective on Illumina from $300.00 to $350.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 31st. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Citigroup increased their price objective on Illumina from $330.00 to $345.00 and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Finally, Bank of America raised their price target on Illumina from $345.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $330.94.
In related news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $331.39, for a total transaction of $3,313,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $351.66, for a total value of $1,160,478.00. Following the sale, the director now owns 392,204 shares of the company’s stock, valued at approximately $137,922,458.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,629 shares of company stock valued at $18,631,589. Company insiders own 0.54% of the company’s stock.
Shares of ILMN stock opened at $324.14 on Tuesday. Illumina, Inc. has a fifty-two week low of $203.83 and a fifty-two week high of $372.61. The firm has a market capitalization of $48.23 billion, a PE ratio of 81.04, a PEG ratio of 2.43 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The business had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. During the same quarter last year, the business posted $1.11 earnings per share. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/06/mn-services-vermogensbeheer-b-v-buys-600-shares-of-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Bear Market
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.